50% of the Revenue Contribution by the Leading Players

The hypoparathyroidism treatment market is largely dominated by the major players, who are competing on the basis of market penetration and distribution. The consolidated nature of the hypoparathyroidism treatment market increases the profitability. Factors such as poor efficacy and efficiency of the treatment are hampering the adoption of hypoparathyroidism treatment. However, the growing awareness regarding hypoparathyroidism treatmentand number of thyroid surgeries are expected to create growth opportunities for the manufacturers operating in the global hypoparathyroidism treatment market. Shire-NPS Pharmaceuticals, Inc., EnteraBio Ltd., and Teva Pharmaceutical Industries Ltd. hold more than 50% revenue share in the global hypoparathyroidism treatment market. The growth of the global hypoparathyroidism treatment market is primarily driven by growing prevalence of hypoparathyroidism and increasing number of thoracic surgeries and incidence of cancer. Thedevelopment of healthcare infrastructure across the globe coupled with governmental support for hypoparathyroidism treatment is expected to drive the growth of the hypoparathyroidism treatment market. The companies operating in the market are involved in developing new experimental hypoparathyroidism treatment drugs.

Increasing Number of Thoracic Surgeries and Incidence of Cancer

The growing screening rates, increasing number of thoracic surgeries and incidence of cancer are expected to be the prime factors driving the growth of the hypoparathyroidism treatment market. Thyroid or neck surgery is associated with hypoparathyroidism, owing to damage to the parathyroid glands. The number of thyroidectomies in the U.S. reflects 39% increase from 2007 to 2015. This indicates transient post-surgical hypoparathyroidism, which can become permanent in about 25% of cases. The growing incidence of head & neck and thyroid cancers is the other factor expected to drive the growth of the market.

Increasing investments in the research and development coupled with the development of biologics is expected to generate momentum and growth opportunities for the hypoparathyroidism treatment market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7857

New Drug Development and Government Support to Root Out Hypoparathyroidism

New drug development is expected to create enormous growth opportunity for the hypoparathyroidism treatment market. Any new curative hypoparathyroidism treatment drug is expected to witness fast adoption with minimal resources due to lack of competition in the hypoparathyroidism treatment market. Symptomatic treatment is the chief goal of hypoparathyroidism treatment as there is no treatment for hypoparathyroidism.

The support to hypoparathyroidism treatment products and initiatives by the governments of different countries such as financial incentives and orphan status are the other factors expected to boost the growth of the hypoparathyroidism treatment market. The demographic drivers of the hypoparathyroidism treatment market include growing geriatric population and healthcare expenditure across the globe.

Growing Purchasing Power and Attractive Reimbursements

In the North America hypoparathyroidism treatment market, the U.S. is expected to be the dominant country as it is a large economy and with high purchasing power. Besides, favorable reimbursements for hypoparathyroidism treatment is also expected to support the growth of the hypoparathyroidism market. Likewise, large presence of major players such as Shire-NPS Pharmaceuticals, Inc., and EnteraBio Ltd., among others, is also expected to drive the growth of the hypoparathyroidism treatment market in the U.S. The healthcare expenditure in the U.S. was almost 16% of its GDP in 2017, which reflects better pricing and market attractiveness for the hypoparathyroidism treatment market.

Request to View Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-7857

Orphan Status and Incentives

The U.S. FDA’s orphan status to drugs and biologics that affect less than 200,000 people in the U.S. confer various incentives such as tax credits for qualified clinical trials and market exclusivity upon regulatory approval. In the hypoparathyroidism treatment market, Natpara is an approved drug with a black box warning notified by the U.S. FDA in January 2015 – enjoying an exclusivity period till 2022.

Competitive Landscape

This section of the report features the profiles of the key players in the hypoparathyroidism treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. The key players operating in the hypoparathyroidism treatment market include Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and EnteraBio Ltd.